DL0410, a candidate for anti-Alzheimer disease with multiple targets in multiple pathways
10.3867/j.issn.1000-3002.2017.10.032
- Author:
LIU AI-LIN
1
;
LIAN WEN-WEN
;
PANG XIAO-CONG
;
ZHOU WEI
;
FANG JIAN-SONG
;
DU GUAN-HUA
Author Information
1. Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
- Keywords:
DL0410;
Alzheimer disease;
multiple targets;
multiple pathways
- From:
Chinese Journal of Pharmacology and Toxicology
2017;31(10):964-964
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To find a promising candidate for anti- Alzheimer disease (AD) with multiple targets in multiple pathways. METHODS A series of classifiers were constructed for predicting the active compounds against 51 key targets toward Alzheimer disease (AD) using the multitarget-quantitative structure- activity relationships (mt- QSAR) method. While drug screening assays were established to evaluate the predicted active molecules. In addition, various cellular models and animal models related with AD were set up to further study the effects of the active compounds. RESULTS A system for the discovery of Multitarget-Directed Ligands against AD was set up and applied, the predicted active compounds were validated by the drug screening assays, and several active compounds with multiple targets were discovered. Among them, DL0410 exerted high activity on H3R, α7nAChR, AChE and ERα, also displayed the most significant effect in improving the ability of memory and learning in several AD animal models. The study on its action mechanisms showed that it's effect may partially through increasing neurotransmitter, inhibiting oxidative emergency, inhibiting the expression of APP, and promoting long- term potentiation. Besides, DL0410 is of more safety than the first- line clinical medicines. CONCLUSION DL0410 is a promising candidate for further development for AD treatment.
